Category Archives: Lunge

1. ESMOupdate 2012, Lung Cancer

Dr. med. Walter Mingrone und Dr. med. Daniel Helbling besprechen die wichtigsten, klinisch relevanten Studien im Bereich Lymphoma, Myeloma and CNS Tumors, die am diesjährigen ESMO (European Society for Medical Onocology) Meeting in Wien präsentiert wurden.

Diskutierte Studien:
How to select amongst available options for the treatment of advanced RCC; B. Escudier

LBA8_PR: Randomized, open label, phase III trial of pazopanib versus sunitinib in first-line treatment of patients with metastatic renal cell carcinoma (mRCC); Results of the COMPARZ trial; R. J. Motzer et al (2. Link)

Poster 1233: Efficacy and Patient (PT)- reported outcomes (pros) with Selumetinib (AZD6244, ARRY-142866; SEL) + Docetaxel (DOC) in Kras-mutant advanced non-small cell lung cancer (NSCLC): a randomized, phase II trial; Janne et al.

4. ASCOupdate 2011, Lungentumore

Diskussionsleiter: Dr. M. Früh, Kantonsspital St. Gallen, bespricht folgende Studien:

Abstract CRA7510: PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC)

Abstract 7503: Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial

Abstract 7507: Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls

Abstract 2501: Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC)

Abstract 7000: Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC).